Iqvia launches new eCOA platform to quantify the patient experience

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/whuwhanfoto)
(Image: Getty/whuwhanfoto)

Related tags: IQVIA, eCOA, Patient centricity, Patient, Patient recruitment, Clinical trial, Clinical development, Software, data analysis, Data management

Iqvia today launched a new “patient centered endpoints” solution, which captures the patient experience during clinical trials and real world studies, says SVP.

As the pharmaceutical industry adopts a more patient-centric view of treatment benefits for new drugs, capturing their experience and integrating feedback into trial design is now a must.

“Collecting direct-from-patient data allows sponsors to strengthen traditional measures and better address patients’ concerns about their experience, which can increase the likelihood of drug approval,” ​said Eric Hodgins, senior vice president, real world and analytics solutions (RWAS) technologies at Iqvia.

The new electronic clinical outcome assessment (eCOA) cloud-based technology platform was released today during the DIA Global Annual Meeting in San Diego, CA. According to the company, the solution is “a science and technology-enabled approach that captures quantified evidence of patients’ experiences during clinical trials and real world studies.”

Hodgins told us the platform enables trial sponsors to better understand – and improve – the patient experience. “The technology features a simple and intuitive interface providing advanced patient assessments that enhance the patient experience and improve data quality – amplifying the patient’s voice to accelerate outcomes,”​ he explained.

The main benefits include reduced timelines, increased efficiency, improved data transparency, and real-time insights about patients, said Hodgins, adding that the product’s key differentiator is its “unparalleled configurability.”

“We flipped the traditional software development lifecycle upside down. This process was cumbersome and required development teams to interpret massive design requirement documents, which typically created cycles of rework and potential for errors,”​ Hodgins said.

“Our solution brings the clinical trial team, who are typically not technical experts, together and allows them to design and adjust the eCOA solution in real-time,”​ he explained. Study teams also can preview the solution on multiple devices at the same time to identify any errors in real-times.

Additionally, the platform features Iqvia’s expanding patient questionnaires library, which lets customers use pre-built and validated assessments for their study.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more